SCHEMBL4121665

SCHEMBL4121665

O=C(Nc1ccc(Cl)cc1)Nc1ccc(OC(F)F)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 8/20 0.58
MEN1 O00255 7/20 0.58
MAPT P10636 5/20 0.58
LMNA P02545 4/20 0.58
HTT P42858 4/20 0.58
NPSR1 Q6W5P4 2/20 0.58
SMN1; SMN2 Q16637 2/20 0.58
CA12 O43570 1/20 0.56
CA1 P00915 1/20 0.56
CA2 P00918 1/20 0.56
CA9 Q16790 1/20 0.56
FPR1 P21462 1/20 0.56
FPR2 P25090 1/20 0.56
ALDH1A1 P00352 3/20 0.55
STING1 Q86WV6 1/20 0.54
KDM4E B2RXH2 1/20 0.52
GAA P10253 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
NPC1 O15118 2/20 0.51
EPHX2 P34913 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4118526 0.91 MAPT (0.66) KMT2AMEN1MAPTLMNAHTT
SCHEMBL4118387 0.89 MAPT (0.60) KMT2AMEN1MAPTLMNAHTT
SCHEMBL4117939 0.86 CNR1 (0.64) KMT2AMEN1MAPTLMNAHTT
Urea SCHEMBL4110289 0.86 MAPT (0.61) KMT2AMEN1MAPTLMNAHTT
SCHEMBL4113538 0.85 MEN1 (0.68) KMT2AMEN1MAPTLMNAHTT
SCHEMBL4121124 0.85 RAB9A (0.67) KMT2AMEN1MAPTLMNAHTT
SCHEMBL4111928 0.85 MAPT (0.68) KMT2AMEN1MAPTLMNAHTT
SCHEMBL4115554 0.85 MEN1 (0.59) KMT2AMEN1MAPTLMNAHTT
SCHEMBL4112376 0.84 EPHX1 (0.65) KMT2AMEN1MAPTLMNAHTT
SCHEMBL4124118 0.84 KMT2A (0.69) KMT2AMEN1MAPTLMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US claimed
EP-1804785-A2 DIARYL UREAS AS CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2007-07-11 EP claimed
WO-2006049941-A2 DIARYL UREAS AS CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2006-05-11 WO claimed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists CNR1, CNR2, OPRL1 KMT2A 2807/4885MEN1 3273/4885MAPT 1654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.